Drug duo tested to shield kidneys after cancer removal
NCT ID NCT06818305
Summary
This study tested whether two existing drugs, finerenone and empagliflozin, could help slow the decline of kidney function in patients at high risk after surgery to remove a kidney for cancer. Researchers compared patients taking one drug, both drugs, or no drug for one year to see which approach was safest and most effective at protecting the remaining kidney.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing
Nanjing, Jiangsu, 210000, China
Conditions
Explore the condition pages connected to this study.